Literature DB >> 6872413

Dose proportionality of amrinone.

J Edelson, G B Park, J Angellotti, R P Kershner, J J Ryan, F G McMahon.   

Abstract

Amrinone was given to 18 healthy subjects in doses of 75, 150, and 225 mg in a randomized crossover design. Plasma levels were shown to rise in proportion to dose. The mean plasma AUC, extrapolated to infinite time, was determined for each dose level; the values obtained were 4, 8.18, and 12.35 micrograms . hr/ml for the 75-, 150-, and 225-mg doses. Mean maximum observed plasma concentrations were 1.03, 1.74, and 2.58 micrograms/ml. At higher doses the extrapolated AUC is more variable, but it is linear over the range of 0.73 to 3.81 mg/kg. The apparent first-order terminal elimination rate is not dose dependent and corresponds to a t1/2 of 3.85 hr.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6872413     DOI: 10.1038/clpt.1983.151

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  4 in total

1.  The relationship between the pharmacokinetics of amrinone in the marmoset and platelet effects.

Authors:  C T Eason; J I Usansky; G P Henry; P Powles; F W Bonner
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1988 Apr-Jun       Impact factor: 2.441

Review 2.  The pharmacokinetics and pharmacodynamics of newer inotropic agents.

Authors:  M L Rocci; H Wilson
Journal:  Clin Pharmacokinet       Date:  1987-08       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of vasodilators. Part II.

Authors:  R Kirsten; K Nelson; D Kirsten; B Heintz
Journal:  Clin Pharmacokinet       Date:  1998-07       Impact factor: 6.447

4.  The pharmacokinetics of amrinone at three dose levels in the rabbit.

Authors:  G E Larijani; M L Rocci; D L Newman; H Wilson
Journal:  Pharm Res       Date:  1985-07       Impact factor: 4.200

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.